Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
نویسندگان
چکیده
منابع مشابه
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1 (GLP-1). Most clinical experience with DPP-4 inhibition is based on vildagliptin (GalvusR, Novartis) and sitagliptin (JanuviaR, Merck). These co...
متن کاملDPP-4 Inhibition in Type 2 Diabetes Management
Insulin resistance manifests itself early in life and involves multiple tissues, including the liver, muscles and adipocytes.1,2 However, as long as the β cell is able to augment its secretion to offset the defect in insulin action, glucose tolerance remains normal.3 With time, however, as the β cell begins to fail, the β cell compensatory response becomes insufficient to offset the insulin res...
متن کاملDPP-4 inhibitors in the treatment of type 2 diabetes.
Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered insulin sensitivity and impaired insulin secretion. Recent advances in the understanding of the physiological functions of incretins and their degrading enzyme dipeptidyl-peptid...
متن کاملLinagliptin: DPP-4 Inhibition in the Treatment of Type 2 Diabetes Mellitus
The complex pathophysiologic mechanisms of type 2 diabetes are one of the barriers that make its treatment so difficult and it is also one of the responsible for the high prevalence of the disease around the world. Patients with T2DM have dysfunction in incretin hormones (such as glucagon-like peptide-1 or GLP-1 and glucose-dependent insulinotropic polypeptide or GIP). By inhibiting the dipepti...
متن کاملGlycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study).
This study investigates changes in A1C following a switch from dual therapy of metformin and DPP-4 inhibitor to a fixed-dose combination (FDC) of metformin + DPP-4 inhibitor following the introduction of the FDC in the provincial formulary. The LMC Diabetes Registry was queried retrospectively for patients with type 2 diabetes, aged between 18 and 80 years with at least one A1C recorded prior a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Vascular Health and Risk Management
سال: 2008
ISSN: 1178-2048
DOI: 10.2147/vhrm.s1944